This article is more than 5 years old. Information may no longer be current.

Bausch & Lomb licenses potential anti-inflammatory from Schering

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ROCHESTER, N.Y. — Bausch & Lomb has obtained exclusive worldwide rights from Schering AG to develop and market a selective glucocorticoid receptor agonist compound for the non-systemic treatment of eye disorders, according press releases issued by the companies.

Bausch & Lomb will evaluate the compound's potential as an ophthalmic anti-inflammatory with an improved safety profile. The project is currently in the preclinical stages, according Bausch & Lomb.

Under the agreement, Bausch & Lomb will make upfront and milestone payments based on development and registration progress, and will make ongoing royalty payments based on sales, according to the release.